Blue Medicare Advantage

Provider Bulletin
May 2023

Carelon Medical Benefits Management, Inc. genetic testing CPT code list update

Effective for dates of service on and after October 1, 2023, the following codes will require prior authorization through Carelon Medical Benefits Management, Inc.*

Note: On March 1, 2023, AIM Specialty Health® began operating as Carelon Medical Benefits Management, Inc.

CPT® code	Description
81418	APOL1 (apolipoprotein L1) (for example, chronic kidney disease), risk variants (G1, G2)
81441	Drug metabolism (for example, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion an
81449	Oncology (oropharyngeal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence
81451	Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incor
81456	Inherited bone marrow failure syndromes (IBMFS) (for example, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, co
0332U	Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (for example, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET),
0355U	Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, 5-50 genes (for example, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1,
0356U	Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes (for example, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT
0363U	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low proba
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis
81355	Vkorc1 (Vitamin K Epoxide Reductase Complex, Subunit 1) (for example, Warfarin Metabolism), Gene Analysis, Common Variants (for example, -1639/3673)

* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.

As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management by accessing Carelon Medical Benefits Management's ***Provider****Portal*SM directly at **www.providerportal.com**.

- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.

If you have questions related to guidelines, please contact Carelon Medical Benefits Management via email at MedicalBenefitsManagement.guidelines@Carelon.com. You can also download a copy of the current upcoming guidelines here: **https://tinyurl.com/yjmjuesk**.